Abstract
The in vitro activity of FK-037, a novel parenteral cephalosporin, was compared to that of ceftazidime, aztreonam and piperacillin (agents often used in empiric regimens in cancer patients) against recent bacterial isolates from patients with cancer. FK-037 was either equal to or 2 to 16-fold more active than the comparative agents against members of theEnterobacteriaceae. It was also active againstAcinetobacter spp.,Aeromonas spp.,Pseudomonas aeruginosa, and otherPseudomonas spp.Xanthomonas maltophilia andAlcaligenes denitrificans were relatively resistant to all four agents. FK-037 was also 4 to 16-fold more active against most gram-positive organisms (including some methicillin-resistant staphylococci) than was ceftazidime.Enterococcus spp.,Listeria monocytogenes andStaphylococcus haemolyticus were relatively resistant to FK-037 and ceftazidime. Overall, FK-037 has a broad antimicrobial spectrum that includes the majority of gram-positive and gram-negative isolates.
This is a preview of subscription content, log in via an institution to check access.
Similar content being viewed by others
References
Bodey GP Infections in cancer patients, a continuing association. American Journal of Medicine 1988, 81, Supplement 1A: 11–26.
Pizzo PA Management of fever in patients with cancer and treatment-induced neutropenia. New England Journal of Medicine 1993, 328: 1323–1332.
Hughes WT, Armstrong D, Bodey GP, Feld R, Mandell GL, Meyers JD, Pizzo PA, Schimpff SC, Shenep JL, Wade JC, Young LS, Yow MD Guidelines for the use of antimicrobial agents in neutropenic patients with unexplained fever. Journal of Infectious Diseases 1990, 161: 381–396.
Fainstein V, Bodey GP, Elting L, Bolivar R, Keating MJ, McCredie KB, Valdivieso M A randomized study of ceftazidime compared to ceftazidime and tobramycin for the treatment of infections in cancer patients. Journal of Antimicrobial Chemotherapy 1983, 12, Supplement A: 101–110.
Pizzo PA, Hathorn JW, Hiemenz J, Browne M, Commers J, Cotton D, Gress J, Longo D, Marshall D, McKnight J, Rubin M, Skelton J, Thaler M, Wesley R A randomized study comparing ceftazidime alone with combination antibiotic therapy in cancer patients with fever and neutropenia. New England Journal of Medicine 1986, 315: 552–558.
Rolston KVI, Berkey P, Bodey GP, Anaissie EJ, Khardori NM, Joshi JH, Keating MJ, Holmes FA, Cabanillas FF, Elting L A comparison of imipienem to ceftazidime with or without amikacin as empiric therapy in febrile neutropenic patients. Archives of Internal Medicine 1992, 152: 283–291.
Fu KP, Foleno BD, Lafredo SC, Lococo JM, Isaacson DM In vitro and in vivo antibacterial activities of FK-037, a novel parenteral broad-spectrum cephalosporin. Antimicrobial Agents and Chemotherapy 1993, 37: 301–307.
Mine Y, Watanabe T, Sakamoto H, Hatano K, Kuno K, Kamimura T, Tawara S, Matsumoto Y, Matsumoto F, Kuwahara S Excellent activity of FK-037, a novel parenteral broad-spectrum cephalosporin, against methicillin-resistant staphylcocci. Journal of Antibiotics 1993, 46: 99–119.
Mine Y, Watanabe Y, Sakamoto H, Hatano K, Kuno K, Higashi Y, Kamimura T, Matsumoto Y, Tawara S In vitro antibacterial activity of FK-037, a novel parenteral broad-spectrum cephalosporin. Journal of Antibiotics 1992, 46: 71–87.
Neu HC, Chin N, Huang H In vitro activity and β-lactamase stability of FK-037, a parenteral cephalosporin. Antimicrobial Agents and Chemotherapy 1993, 37: 566–573.
National Committee for Clinical Laboratory Standards Methods for dilution antimicrobial susceptibility tests for bacteria that grow aerobically. Approved standard M7-A2. NCCLS, Villanova, PA, 1990.
Rolston KVI, Nguyen HT, Ho DH, LeBlanc B, Bodey GP In vitro activity of Ro23-9424, a dual-action anti-bacterial agent, against bacterial isolates from cancer patients compared to those of other agents. Antimicrobial Agents and Chemotherapy 1992, 36: 879–882.
Elting L, Bodey GP, Keefe B Speticemia and shock syndrome due to viridans streptococci. A case controlled study of predisposing factors. Clinical Infectious Diseases 1992, 14: 1201–1207.
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Dholakia, N., Rolston, K.V.I., Ho, D.H. et al. In vitro activity of FK-037, a novel parenteral cephalosporin, against bacterial isolates from neutropenic cancer patients. Eur. J. Clin. Microbiol. Infect. Dis. 13, 679–685 (1994). https://doi.org/10.1007/BF01974000
Issue Date:
DOI: https://doi.org/10.1007/BF01974000